Does Jisandai (Bingtonsha) belong to the national free drug category?

Epclusa (Epclusa), as an innovative oral anti-HCV drug, was developed by Gilead of the United States. It cleverly combines Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir) The active ingredient has shown excellent therapeutic effects against chronic hepatitis C virus (HCV) infection of all genotypes. It is regarded as a breakthrough in the field of hepatitis C treatment and has been widely used worldwide.

However, regarding the question of whether Jisandai (Bingtongsha) is a free national drug, the answer is no. Although the Chinese government is sparing no effort to promote the prevention and treatment of hepatitis C, Jisandai (bingtonsa) has not yet been included in the national essential medicine list, nor has it become part of any large-scale free medicine program. If patients wish to use GISANDA (Bingtonsa) for treatment, they usually have to bear the cost themselves or obtain partial reimbursement through commercial medical insurance. China's basic medical insurance system may cover part of the cost of Jisandai (Bingtonsha), but the specific reimbursement ratio and conditions will vary from region to region.

It is worth mentioning that the state still provides certain support for the treatment of hepatitis C patients. In recent years, China has stepped up hepatitis C screening and launched hepatitis C treatment programs for special groups in some areas. These programs may provide free screening and some treatment support, but do not cover all antiviral drugs.

In order to reduce the financial burden on patients, Gilead and some non-governmental organizations have implemented drug assistance projects in some areas, providing more favorable pricesGilsa (Bintongsa), or providing free drugs to some patients under certain circumstances. However, these assistance measures are not equivalent to a free drug policy at the national level. Their application conditions are relatively harsh and their coverage is limited.

In summary, although Jisandai (Bingtonsa) is not a free drug in the country, its importance in the treatment of hepatitis C cannot be ignored. When considering the use of Jisandai (Bingtonsa), patients should first consult their doctor to understand the treatment plan that is most suitable for them. At the same time, attention should also be paid to local policies, insurance reimbursement status, and pharmaceutical assistance programs to reduce financial pressure as much as possible.